When Naomi Osaka opened up about her anxiety and depression at the 2021 French Open, it sparked a conversation in sports — ...

Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, ...

Mental health has not always been talked about within communities of color, but that is starting to shift because of people ...

The latest update from the National Hurricane Center now shows a medium chance of development near Florida or along the ...

Many of the traditions we know today began in postwar America — including the very color of many modern wedding dresses.

Sonya Johnson, 41, started taking drugs at age 11, when a man who was sexually abusing her gave them to her behind her ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

Mark Duplass, best known as Chip Black on the Apple TV+ series, recently opened up about his long and personal journey with mental health.

As the first lawsuits loomed in the late 1990s, Johnson & Johnson attempted to shift its Baby Powder liabilities onto a shell company with limited funds. Only when a judge blocked this Hail Mary ...

Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy J&J said aticaprant showed insufficient efficacy in a Phase 3 test in major depressive disorder.

Johnson & Johnson (NYSE:JNJ) has decided to discontinue a Phase 3 program for its depression therapy aticaprant due to insufficient efficacy, the pharma giant announced. Known as VENTURA, the ...

Johnson & Johnson’s other depression drug Spravato (esketamine), in January, received FDA approval as the only monotherapy for adults living with major depressive disorder who have had an ...